Neurogene (NGNE) Long-Term Investments (2014 - 2017)

Neurogene has reported Long-Term Investments for 4 years, with the latest figure at $20.0 million in Q1 2017.

• For the quarter ending Q1 2017, Long-Term Investments fell 48.2% year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2017 stood at $20.0 million (down 48.2% YoY), and the FY2016 full-year result was $50.0 million, up 30.13% from the prior year.
• Long-Term Investments for Q1 2017 stood at $20.0 million, down from $50.0 million in the prior quarter.
• The five-year high for Long-Term Investments was $50.0 million in Q4 2016, with the low at $2.0 million in Q4 2014.
• Historically, Long-Term Investments has averaged $24.8 million across 4 years, with a median of $20.0 million in 2017.
• Annual changes were most pronounced in 2015 — Long-Term Investments jumped 1820.02% — and 2017, when it tumbled 48.2%.
• Neurogene's Long-Term Investments stood at $2.0 million in 2014, then jumped by 1820.02% to $38.5 million in 2015, then surged by 30.13% to $50.0 million in 2016, then tumbled by 60.02% to $20.0 million in 2017.
• The last three Long-Term Investments figures came in at $20.0 million (Q1 2017), $50.0 million (Q4 2016), and $16.7 million (Q3 2016), per Business Quant data.